Vir Biotechnology Inc (VIR)
Return on total capital
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -684,305 | -695,791 | -314,095 | -324,131 | 833,070 | 1,555,324 | 1,306,975 | 1,593,214 | 420,751 | -259,405 | -293,635 | -383,703 | -296,980 | -252,335 | -212,400 | |||
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 1,590,240 | 1,675,080 | 1,810,210 | 1,970,760 | 2,077,960 | 2,149,860 | 1,952,010 | 2,001,010 | 1,431,850 | 876,274 | 737,325 | 650,951 | 716,852 | 812,355 | 563,779 | 380,333 | 423,942 | -280,797 |
Return on total capital | -43.03% | -41.54% | -17.35% | -16.45% | 40.09% | 72.35% | 66.96% | 79.62% | 29.39% | -29.60% | -39.82% | -58.94% | -41.43% | -31.06% | -37.67% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-684,305K ÷ ($—K + $1,590,240K)
= -43.03%
Vir Biotechnology Inc's return on total capital has shown significant fluctuations over the past eight quarters. The return on total capital was negative during the most recent two quarters, Q4 2023 and Q3 2023, at -43.03% and -41.54% respectively, indicating that the company is generating a lower return relative to its total capital base. This negative trend continued from the positive returns seen in the previous quarters of 2022.
The return on total capital experienced a sharp decline in Q2 2023 at -17.35% compared to the previous quarter, Q1 2023, at -16.45%. This downward trend contrasts with the robust performance in 2022, where the return on total capital exceeded 40% in each quarter.
The substantial decrease in the return on total capital in 2023 raises concerns about the company's ability to efficiently utilize its capital resources to generate profits. Investors and stakeholders may closely monitor future financial performance to assess the company's strategic direction and operational efficiency.
Peer comparison
Dec 31, 2023